Published research on ReadiSorb® Liposomal Glutathione.
Each of the following studies has been independently researched, peer-reviewed, and can be viewed on PubMed.
11. Restoring Cytokine Balance in HIV-Positive Individuals with Low CD4 T Cell Counts.
Published May, 2017 in the journal AIDS Research and Human Retroviruses.
In summary, supplementation with L-GSH in HIV-infected individuals with CD4+ T cell counts below 350 cells/mm3 can help restore redox homeostasis and cytokine balance, therefore aiding the immune system to control opportunistic infections.
10. Liposomal Glutathione Supplementation Restores TH1 Cytokine Response to Mycobacterium tuberculosis Infection in HIV-Infected Individuals.
E-Published July, 2015 in the Journal of Interferon & Cytokine Research.
Furthermore, we demonstrate that supplementing individuals with HIV infection for 13 weeks with liposomal GSH (lGSH) resulted in a significant increase in the levels of TH1 cytokines, IL-1β, IL-12, IFN-γ, and TNF-α. lGSH supplementation in individuals with HIV infection also resulted in a substantial decrease in the levels of free radicals and immunosuppressive cytokines, IL-10 and TGF-β, relative to those in a placebo-controlled cohort.
9. Investigating the causes for decreased levels of glutathione in individuals with type II diabetes.
Published March, 2015 in the Journal PLOS One.
Overall, the findings suggest that lower levels of GSH in individuals with T2DM lead to their increased susceptibility to M. tb infection.
8. An elucidation of neutrophil functions against Mycobacterium tuberculosis infection.
E-published November, 2013 in the journal Clinical & Developmental Immunology
They characterized the functions of neutrophils in response to Mycobacterium tuberculosis (M. tb) infection, with particular reference to glutathione (GSH).
7. Characterization of dendritic cell and regulatory T cell functions against Mycobacterium tuberculosis infection.
Published May, 2013 in BioMed Research International
The results indicate that GSH by its direct antimycobacterial activity inhibits the growth of intracellular M. tb inside DCs (dendritic cells).
6. Glutathione Supplementation Improves Macrophage Functions in HIV.
Published February, 2013 in the Journal Interferon and Cytokine Research
The results indicate that HIV infection leads to increased production of free radicals and decreased production of GCLC resulting in depletion of rGSH and this may lead, in part, to the loss of innate immune function observed in HIV patients.
5. Oral pretreatment with liposomal glutathione attenuates reperfusion injury in rabbit isolated hearts.
Published November, 2012 in the Journal of Cardiovascular Pharmacology
Hearts from lipGSH-treated rabbits exhibited better recovery of left ventricular contractile function during reperfusion and had attenuated oxidative damage. Furthermore, hearts from lipGSH-treated animals had increased myocardial tissue levels of GSH demonstrating effective absorption of lipGSH.
4. A clinical trial of glutathione supplementation in autism spectrum disorders.
Published December, 2011 in Medical Science Monitor.
The results suggest that oral ... glutathione supplementation may have some benefit in improving some of the transsulfuration metabolites. Future studies among subjects diagnosed with an ASD should further explore the pharmacokinetics of glutathione supplementation and evaluate the potential effects of glutathione supplementation upon clinical symptoms.
3. Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells.
Published October, 2010 in Neurochemical Research.
No toxicity was observed with the liposomal preparation at 200-fold the EC(50) for repletion. These findings indicate that glutathione supplied in a liposomal formulation holds promise as a potential therapeutic for neuronal maintenance.
2. Aminothiol receptors for decorporation of intravenously administered (60)Co in the rat.
Published December, 2010 in Health Physics Society.
Liposomal encapsulation was found to markedly enhance the oral bioavailability of GSH compared to non-formulated GSH. The oral administration of liposomal GSH reduced (60)Co levels in nearly all tissues by 12-43% compared to that observed for non-formulated GSH. Efficacy of oral Cys was only slightly reduced in comparison with intravenous Cys.
1. Anti-oxidant and anti-atherogenic properties of liposomal glutathione: studies in vitro, and in the atherosclerotic apolipoprotein E-deficient mice.
Published December, 2007 in the Journal Atherosclerosis.
We thus conclude that liposomal glutathione possesses anti-oxidative and anti-atherogenic properties towards lipoproteins and macrophages, leading to attenuation of atherosclerosis development.